Teijin Pharma and Scynexis Sign Research Agreement
News Oct 14, 2005
Teijin Pharma Limited, a wholly owned subsidiary of Teijin Limited, and Scynexis have signed an agreement under which Scynexis will provide comprehensive medicinal and analytical chemistry services to Teijin Pharma's research programs.
The agreement provides Teijin Pharma with dedicated chemistry resources including a highly experienced Scynexis medicinal chemistry team backed by proprietary, innovative technologies.
“Scynexis is pleased to work with Teijin Pharma in its novel drug discovery and development efforts and to have Teijin Pharma as one of Scynexis' valued customers in the important Japanese market,” said Yves Ribeill, President and Chief Executive Officer of Scynexis.
“Scynexis has now firmly established relationships in Japan, Europe and the U.S. confirming its ability to deliver valuable capabilities and technologies to a wide range of customers.”
Researchers at the Crick and Imperial College London have generated malaria parasites resistant to a promising new class of candidate antimalarial drugs. By analyzing the structural changes behind the resistance, they identified novel compounds that were immune to this mechanism of resistance.READ MORE